- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA ruled Pfizer in breach after two regional account directors had been in post for 2 years without passing the ABPI Medical…
PMCPA case summary: Anonymous non-contactable complainant vs PharmaMar (AUTH/2979/9/17). Case details, clauses, outcome and sanctions were not stated in the provided case…
A GP complained a Novartis-sponsored Entresto presentation was unbalanced and omitted side effects. The PMCPA Panel found the overall meeting included safety/SPC…
AstraZeneca’s HCP website content for Onglyza and Symbicort COPD was ruled misleading due to layout/undue emphasis on relative effects. Forxiga and Symbicort…
A health professional alleged Otsuka’s Jinarc training portal was promotional, lacked compliant prescribing info and improperly referenced the MHRA. The Panel found…
Allergan’s tender-related presentation reused Hunt & Clarke animal assay data in a way that implied Botox was more potent than Xeomin, contrary…
A two-page Amias ad compared ARBs in heart failure and marked losartan as a black triangle drug. PMCPA held this implied all…
Patients attended and spoke at a Sanofi-Aventis promotional meeting where Multaq was promoted, leading to a breach for advertising a POM to…
A doctor complained a Pradaxa promotional email was sent to his NHS account and had no unsubscribe link. Panel found consent likely…
BMJ analysis suggested Amgen had unreported EUCTR trial results. Panel found two trials were out of UK Code scope (no UK nexus)…
A GP alleged a sponsored pre-licence article improperly shared an unconfirmed linagliptin price as “advance notification”. Panel held the article was not…
UCB voluntarily admitted a paid advertorial in a Parkinson’s Disease supplement distributed with The Times that named Keppra and Neupro (POMs). PMCPA…
PMCPA case AUTH/3083/9/18 (Director v Eisai) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…
BMJ EUCTR compliance paper triggered a PMCPA complaint about late trial results posting. Panel initially found a Clause 9.1 breach for one…
Merz ads comparing Xeomin/Bocouture with Botox/Vistabel used “equipotent/equal potency” and “1:1 conversion” with side-by-side vials. Panel found misleading; Appeal Board also found…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.